Cynvenio Biosystems announced the nationwide availability of its LiquidBiopsy platform, which utilizes a blood sample to perform sequence analysis and genomic reporting.
This platform gives doctors and cancer researchers the ability to perform next-generation sequencing (NGS) on rare populations of circulating tumor cells (CTCs) and cell-free DNA from whole blood.
Cynvenio’s LiquidBiopsy simultaneously analyzes DNA from CTCs as well as circulating tumor DNA, which studies have shown help target therapies and track tumor response.
"Cynvenio has solved the problem of molecularly detecting extremely rare cells in the bloodstream that are known to drive the metastatic process," said André de Fusco, CEO of Cynvenio.
Cynvenio’s LiquidBiopsy is a turn-key platform for academic and pharma R&D programs in oncology.
It was recently selected by Thermo Fisher Scientific for distribution as an integrated solution with their Ion Torrent Next Generation Sequencing Platform for clinical research applications. Cynvenio’s automated rare cell workflow makes it a cost-effective and easy choice for a wide array of personalized cancer research projects, especially those focused on DNA sequencing from blood.
Cynvenio’s LiquidBiopsy platform is used to monitor tumor response through the identification of DNA mutations in 50 genes commonly altered in cancer.
It is compatible with larger (and smaller) gene panels which can be created as required. LiquidBiopsy is optimized for Thermo Fisher Scientific’s NGS sequencers with full support for other downstream analysis methodologies.